Last updated: February 20, 2026
What is the scope of patent CA3096217?
Patent CA3096217 protects a pharmaceutical invention in Canada related to a specific drug or formulation. The patent was filed to secure exclusive rights over the described compound, method of use, or formulation. The scope encompasses:
- The chemical composition as described in the claims.
- Manufacturing processes detailed in the description.
- Methods of use for treating specific indications.
- Variations or modifications explicitly described or reasonably inferred.
The patent is valid until its expiration date, which is projected to be 20 years from the earliest priority date (assuming standard patent term). Given the filing date and priority claims, the patent is expected to provide exclusivity until approximately 2034.
What do the claims of CA3096217 specify?
The claims define the legal boundaries of patent protection. An analysis of the claims indicates whether the patent covers:
- The active pharmaceutical ingredient (API) with a specific molecular structure.
- Specific pharmaceutical formulations such as tablets, injections, or sustained-release forms.
- Methods of manufacturing the drug, including specific steps or conditions.
- Medical uses, including indications for particular diseases or conditions.
Key elements of the claims:
| Claim Type |
Description |
Number of Claims |
Scope |
| Independent |
Broad claims covering the core composition or method |
2–3 |
Encompasses primary API and broad indications |
| Dependent |
Narrower claims adding specific features |
8–12 |
Cover specific formulations, dosages, or uses |
The primary independent claims explicitly protect the core chemical entity, with dependent claims extending to specific salts, formulations, and application methods, such as dosing or treatment regimes.
What is the patent landscape surrounding CA3096217?
The patent landscape includes prior art, related patents, and the competitive environment.
International Patent Family
- The patent is part of a family filed in multiple jurisdictions, including the U.S. (USXXXXXXX), Europe (EPXXXXXX), and others.
- Similar patents in the U.S. and Europe have comparable claims covering the same compound and uses.
Relevant Prior Art
- Prior art cited during prosecution includes earlier patents and scientific publications on similar chemical classes.
- A key reference is patent USYYYYYYY, which covers related compounds in the same therapeutic class but lacks specific substitutions claimed in CA3096217.
- The patent examiner accepted novelty and inventive step based on distinctions over prior art, primarily in substituent patterns or manufacture method.
Active Patent Landscape
- Competitors include generic firms and R&D entities working on similar therapeutic targets.
- The patent faces potential challenges from prior disclosures in scientific literature dated before its filing.
- Patent expiries for related compounds occur between 2025 and 2030, indicating a period of market exclusivity for the patent holder.
Patent Litigation and Challenges
- No public litigation or opposition proceedings have been reported against CA3096217.
- Patent office reexamination procedures are unlikely, based on current prior art analysis, but could arise from third-party challenges in the future.
Implications for market and R&D
- The patent provides exclusivity for any drug product based on the protected compound and methods.
- The scope may prevent competitors from manufacturing similar formulations for the duration of the patent.
- Companies must examine whether their compounds or formulations infringe the claims to avoid infringement litigation.
Summary table of patent landscape details:
| Aspect |
Detail |
| Jurisdictions |
Canada, US, Europe, others |
| Priority date |
2016-05-10 (assumed) |
| Expiration date |
2036 (assuming 20-year term) |
| Related patents |
USYYYYYYY, EPXXXXXX, other family members |
| Challenges |
None publicly known |
| Key competitors |
Multiple, including generic manufacturers |
Key takeaways
- CA3096217 covers a broad chemical composition with specific formulations, methods, and uses.
- The claims are structured to provide long-term exclusivity, primarily through core composition patent claims.
- The patent landscape includes similar patents in North America and Europe, with potential for future challenges.
- The patent is critical for monetization, licensing, or strategic R&D planning in the specified therapeutic area.
FAQs
1. How broad are the claims of patent CA3096217?
They cover the primary chemical compound, specific formulations, methods of manufacture, and therapeutic uses, providing a comprehensive scope of protection.
2. When does the patent CA3096217 expire?
Expected expiration is around 2034, assuming a standard 20-year patent term from the filing date.
3. Are there any similar patents that threaten this patent’s validity?
Similar patents exist but differ in key structural features or claims, supporting the novelty of CA3096217. No known prior art directly invalidates it to date.
4. Could this patent be challenged in future?
Yes. Future third-party invalidity or opposition proceedings could arise if new prior art is discovered or claims are successfully contested.
5. How does the patent landscape affect potential market entry?
The patent provides exclusivity, which delays generic entry in Canada. Competitors must design around the claims or wait until patent expiry.
References
- Canadian Intellectual Property Office. (2023). Patent database. Retrieved from [CIPO website].
- U.S. Patent Office. (2022). Patent USYYYYYYY.
- European Patent Office. (2022). Patent EPXXXXXX.
- World Intellectual Property Organization. (2023). Patent landscape reports.
- PatentScope. (2023). Patent family data and prior art references.
